GXAI

Gaxos.AI is a Nasdaq micro-cap ($11.9M market cap) that only began generating meaningful revenue in FY2025 — $1.93M against $256 in FY2023 and $4.03K in FY2024. The headline +47,901.7% growth is an artifact of a near-zero base, not a durable trend, so it tells you almost nothing about demand. Every year since 2022 has been a loss: net income of -$3.90M in FY2025 on operating income of -$4.92M, for an operating margin of -254%. The MD&A reads like a spray of unrelated launches — a game-asset generator, UnGPT.ai (explicitly marketed to 'surpass existing AI detection tools' for 'undetectable output'), Art-Gen.AI, Bible Pray AI, Gaxos Health, an RNK Health peptides JV — with no evidence any one of them is scaling. This is a portfolio of ideas, not a business with a proven, focused product-market fit.

The balance sheet is where this becomes an avoid rather than a speculative hold. Liabilities are trivial ($681K, 0.05x equity) and reported equity is $13.1M, but cash and equivalents are just $840K while operating cash flow burned -$3.85M in FY2025. At that pace the company has well under three months of cash — it must raise capital, and shares already grew 43.5% year-over-year (including 200,000 restricted shares issued to acquire software from Abraco LLC). Retained earnings sit at -$12.7M of accumulated deficit. Reported current assets of $12.6M vastly exceed the $840K of actual cash, and the provided data does not disclose what that difference is, so I can't verify how much is liquid enough to fund the burn.